Health · Medical Research · 2 hrs ago
Wegovy trial finds lower BMI in children aged 6 to under 12
Novo reported results from a late-stage Wegovy trial involving children aged 6 to under 12 with obesity.
After 68 weeks, children who stayed on the drug had an average BMI decrease of 17.4%, while the placebo group’s BMI rose 2.2%.
All 167 children also received diet and activity changes during the trial.
Wegovy is approved for obesity in children aged 12 and older, but no medication is approved for obesity in children under 12.
Novo said the drug’s safety and tolerability were consistent with adult trials, with no observed concerns about growth or puberty.
The two-year study leaves long-term effects unclear, and Novo said more research is needed on treatment as children grow into adulthood.
Novo Nordisk said its Wegovy injection lowered body mass index in children aged 6 to under 12 with obesity in a late-stage trial.
At 68 weeks, BMI fell 17.4% among children receiving Wegovy and rose 2.2% among those receiving a placebo, assuming they stayed on treatment.
More than 40% of children treated with Wegovy were no longer classified as having obesity after 68 weeks, under the same assumption.
The company said the drug’s safety and tolerability were consistent with results in adults, with no observed concerns related to growth or pubertal development.
The two-year study did not establish whether earlier treatment changes obesity’s long-term course or what treatment and maintenance would look like as children reach adulthood.
- Who
- Novo Nordisk and children aged 6 to under 12 with obesity.
- What
- A late-stage trial found that Wegovy lowered children’s BMI compared with a placebo.
- When
- Full trial results were released on Monday, November 16, 2026.
- Where
- Not stated
- Why
- The results may help address the lack of approved medicines for obesity in children under 12.
This story does not have two clearly opposing sides.
Novo initially shared that more than 40% of children treated with Wegovy were no longer classified as having obesity after 68 weeks, assuming they stayed on treatment.
Novo released full results from the late-stage trial.
- Trial age range
- 6 to under 12 years
- Trial duration
- 68 weeks
- BMI change with Wegovy
- Fell 17.4% among children who stayed on treatment
- BMI change with placebo
- Rose 2.2% among children who stayed on treatment
- Study participants
- 167 children, all receiving lifestyle modifications
3 sources
What people are saying
This is a very significant disease burden in this very young patient population
We are driving towards control of this chronic disease in that patient population when they are still so young and at such high risk for more advanced and accelerated disease progression because they developed it so early
That is something that is still an evidence gap